Effect of Tamoxifen Citrate on Canine Immobilization (Disuse) Osteoporosis

The effect of tamoxifen citrate on bone mass in immobilization osteoporosis was studied in 11 growing dogs. Immobilization osteoporosis was induced by fiberglass cast immobilization of the right hindlimb for 28 days, while the left hindlimb served as a nonimmobilized control. Six dogs received tamoxifen citrate (1.5 mg/kg per os) once daily for 28 days; five dogs received no treatment. All dogs were euthanatized on day 28 and bone samples were collected. Bone mineral content of the distal tibial metaphysis of casted and uncasted limbs was measured by single photon absorptiometry. Immobilization resulted in a significant reduction in bone mass in the casted limb of untreated and tamoxifen-treated dogs. However, tamoxifen-treated dogs had less severe immobilization osteoporosis than untreated dogs. The calculated bone mass sparing effect of tamoxifen was 24.4%. Because of the complexity of pathologic bone remodeling, use of a single therapeutic agent may not be the optimal means of preventing bone loss associated with immobilization.